[MOL] More Information about Multiple Myeloma and Hycamtin [12769] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] More Information about Multiple Myeloma and Hycamtin



My Dear friends, I thought this series of information about Multiple
Myeloma and new treatment available would not only brighten your day,
but help us with a clearer understanding in order for those caregivers
to learn and help research the necessary topics to this disease in order
to provide the survivor with options. Hope it benefits.

God Bless
marty auslander



Hycamtin Shows Promising Results in Phase II Trial

In this phase II clinical trial, patients (n=46) with refractory or
relapsed
multiple myeloma who had received one prior chemotherapy treatment were
administered Hycamtin 1.25 mg/m2 as a 30 minute infusion for five
consecutive
days every three weeks.  Patients received a median of four cycles of
Hycamtin.   Some patients also received granulocyte-colony stimulating
factor
(G-CSF) if they developed grade three or four neutropenia following the
first
course of chemotherapy.  The median time from first treatment for
multiple
myeloma to the initiation of treatment with Hycamtin was 13 months.

Forty-three patients were evaluable for response; the overall response
rate
was 16 percent (response was defined as at least a 50 percent reduction
in
monoclonal protein levels in the blood).  Patient responses were
sustained at
least 70 days, with some patients responding for more than 477 days. 
The
median progression-free survival time was 13 months, and the median
survival
time was 28 months.

"This study is significant because most agents demonstrate little
activity as
a single-agent for relapsed myeloma in clinical studies.  Response rates
are
usually higher when combination treatments are used, so we look forward
to
seeing results from combination studies involving Hycamtin," said Dr.
Kraut.

As with most chemotherapeutic agents, the most commonly reported side
effect
was myelosuppression which was dose-limiting.  Thrombocytopenia and
anemia
were also frequent complications.  More than half the patients
experienced
mild vomiting or diarrhea.


Multiple Myeloma

Multiple myeloma is a cancer of the bone marrow that is related to
leukemia
or lymphoma and is characterized by an uncontrolled growth of plasma
cells.
In otherwise healthy adults, plasma cells comprise less than 5 percent
of
bone marrow cells.  People with multiple myeloma, however, have large
numbers
of plasma cells in their bone marrow (usually more than 10 percent and
often
more than 90 percent of bone marrow cells).

Multiple myeloma accounts for about 10 percent of all hematologic
cancers.
An estimated 12,000 new cases occur each year.  The disease is most
common
among individuals ages 50-70, with peak incidence occurring between ages
60-65.  Median survival time with currently used single-agent therapies
is 6
to 25 months.
------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------